Gilead(US:GILD)2025-02-12 01:42Financial Performance - FY24 Total Product Sales excluding Veklury increased by 8% year-over-year to $26.8 billion[9] - FY24 Total HIV sales increased by 8% year-over-year, contributing approximately $1.4 billion in sales growth[9] - FY24 Trodelvy sales increased by 24% year-over-year, driven by global demand[9] - Q424 Total Product Sales excluding Veklury increased by 13% year-over-year to $7.2 billion, driven by HIV, Oncology, and Liver Disease[9] - Q424 HIV product sales increased by 16% year-over-year to $5.5 billion[12] - Q424 Oncology product sales increased by 10% year-over-year to $843 million[12] Product Pipeline and Regulatory Updates - Lenacapavir for PrEP was filed in the U S with a potential launch estimated in Summer 2025[9] - Lenacapavir for PrEP MAA and EUM4All applications were filed with EMA with a potential launch in 2H25[9] - Anito-cel demonstrated potential best-in-class Ph2 iMMagine-1 data in R/R MM at ASH 2024[9] - First patient dosed in Ph3 iMMagine-3 trial for anito-cel in 2-4L R/R MM[9]